← All diseases Rare and hereditary disorders

Hereditary ATTR amyloidosis

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchOnly the strongest evidence (80)Meta-analysis (11)Treatment guideline (1)Phase 3 study (30)Randomized trial (23)Systematic review (15)Clinical trial (344)Review article (146)Early study (phase 1 or 2) (7)Case report (135)Laboratory or animal study (8)Commentary or editorial (72) Studies currently recruiting participants only (35)

Filter

Publications (1019)

• Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis. (2024/01/01) ♡
• Characterization of the G-quadruplexes in the transthyretin gene and its role in silencing transthyretin mRNA transcription. (2024/01/01) ♡
• Prevalence of transthyretin cardiac amyloidosis in patients hospitalized for heart failure with preserved ejection fraction and septal thickness. (2024/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. What's new in cardiac amyloidosis? Pharmacological treatment, physical activity, and care of patients with transthyretin cardiac amyloidosis. (2024/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Amyloidosis and the Syncopal Enigma. (2024/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Utility of Genetic Testing in Patients with Transthyretin Amyloid Cardiomyopathy: A Brief Review. (2023/12/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Electrocardiographic heterogeneity of patients with variant transthyretin amyloid cardiomyopathy: Genotype-phenotype correlations. (2023/12/15) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin. (2023/12/15) ♡
• Hereditary Transthyretin Amyloidosis: How to Differentiate Carriers and Patients Using Speckle-Tracking Echocardiography. (2023/12/09) ♡
• Neuropathy progression in hereditary transthyretin amyloidosis (ATTRv) patients after liver transplantation. (2023/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study. (2023/12/01) ♡
• Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay. (2023/12/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Neurological onset in patients with V122I hereditary transthyretin amyloidosis: a glitch in the paradigm. (2023/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Strong positive light chain immunostaining in a patient with transthyretin amyloidosis. (2023/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Ophthalmological involvement in wild-type transthyretin amyloidosis: A multimodal imaging study. (2023/12/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis. (2023/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. False Negative (99m)Tc-DPD Scintigraphy in pVal50Met (Val30Met) Hereditary Transthyretin Amyloidosis. (2023/11/21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Importance of genetic study in elderly patients with transthyretin cardiac amyloidosis. (2023/11/10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). (2023/11/10) ♡
• Occupational practice in patients with hereditary transthyretin amyloidosis, a qualitative study. (2023/11/10) ♡
• Hereditary transthyretin amyloidosis in the era of RNA interference, antisense oligonucleotide, and CRISPR-Cas9 treatments. (2023/11/09) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A rare pathogenic variant identified in a heart transplant recipient with hereditary transthyretin amyloidosis: a case report. (2023/11/01) ♡
• A simple ATTR-CM score to identify transthyretin amyloid cardiomyopathy burden in HFpEF patients. (2023/11/01) ♡
• Transthyretin amyloid cardiomyopathy among patients hospitalized for heart failure and performance of an adapted wild-type ATTR-CM machine learning model: Findings from GWTG-HF. (2023/11/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survival. (2023/11/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). (2023/10/26) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Case of hereditary Y69H (p.Y89H) transthyretin variant leptomeningeal amyloidosis presenting with drop attacks and recurrent transient language disorder. (2023/10/25) ♡
• Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. (2023/10/17) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Severe chronic diarrhoea caused by hereditary transthyretin amyloidosis. (2023/10/16) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. (2023/10/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. (2023/10/05) ♡
• Targeted sequencing of selected functional genes in patients with wild-type transthyretin amyloidosis. (2023/10/02) ♡
• Multimodality imaging of simultaneous occurrence of cardiac transthyretin amyloidosis and cardiac sarcoidosis. (2023/10/01) ♡
• Magnetic resonance neurography and diffusion tensor imaging of the sciatic nerve in hereditary transthyretin amyloidosis polyneuropathy. (2023/10/01) ♡
• Valve disease in cardiac amyloidosis: an echocardiographic score. (2023/10/01) ♡
• Quantification of muscle involvement in familial amyloid polyneuropathy using MRI. (2023/10/01) ♡
• Strain-derived myocardial work in wild-type transthyretin cardiac amyloidosis with aortic stenosis-diagnosis and prognosis. (2023/10/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France. (2023/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis. (2023/10/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current Evidence Supporting the Role of Immune Response in ATTRv Amyloidosis. (2023/09/29) ♡
• Role of Saturation and Length of Fatty Acids of Phosphatidylserine in the Aggregation of Transthyretin. (2023/09/20) ♡
• EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates. (2023/09/15) ♡
• Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study. (2023/09/13) ♡
• Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals. (2023/09/05) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Black Women and Transthyretin Amyloidosis: Insights From the Women's Health Initiative. (2023/09/01) ♡
• Popeye Sign in Hereditary Transthyretin Amyloidosis. (2023/09/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. The serum level of plasmin-alpha2 plasmin inhibitor complex (PIC) is useful for differentiating cardiac light chain amyloidosis from transthyretin amyloidosis. (2023/09/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Quantitative sensory testing and skin biopsy findings in late-onset ATTRv presymptomatic carriers: Relationships with predicted time of disease onset (PADO). (2023/09/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Neurological manifestations of ATTR amyloidosis]. (2023/09/01) ♡
• Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca. (2023/08/31) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.